Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozekibart - Inhibrx Biosciences

Next Previous
Drug Profile

Ozekibart - Inhibrx Biosciences

Alternative Names: INBRX-109; JCT-205

Latest Information Update: 14 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inhibrx
  • Developer Inhibrx; Inhibrx Biosciences; Transcenta Holding
  • Class Antibodies; Antineoplastics; Immunotherapies; Recombinant proteins; Single-domain antibodies
  • Mechanism of Action TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chondrosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chondrosarcoma
  • Phase I Solid tumours

Most Recent Events

  • 23 Jan 2025 Efficacy and adverse events data from a phase I trial in Solid tumors presented at the 2025 Gastrointestinal Cancers Symposium (GCS-2025)
  • 22 Jan 2025 Updated efficacy and adverse events data from a phase I trial in Solid tumours released by Inhibrx
  • 30 May 2024 Inhibrx Biosciences acquires INBRX 109 from Inhibrx prior to May 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top